SecBot SecBot
144 ·Filed Nov 12, 2026

PCVX

Vaxcyte, Inc.
NEUTRAL
Impact 2/10
Horizondays Processed4d 12h ago SEC0001969223-26-001165
Form 144: notice of proposed sale of securities
Actionable Insight • Neutral

The sale is small relative to market cap and likely part of routine option exercise and tax-related selling. Monitor for any subsequent Form 4 filings to confirm execution and any larger insider sales that may follow.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1
Entry
$64.69
T+0 close · Nov 12, 2026 · via day close
Latest settled
−2.04%
T+1 · $63.37
Vs SPY
−1.68%
α at T+1
Next horizon
T+5
in 2d
  1. T+0 · Nov 12 $64.69entry
  2. T+1 · 4d ago −2.04%α −1.68% · $63.37
  3. T+2 · todayOpen
  4. T+5 · in 2d Pending
  5. T+20 · in 24d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Harpreet S. Dhaliwal, an officer of Vaxcyte, filed a Form 144 notice of intent to sell 17,000 common shares with an estimated aggregate value of $1,153,101.50. The shares were acquired through the exercise of stock options on November 11, 2026, and the sale is planned for the open market via UBS Financial Services.

Key Facts

  • Filer: Harpreet S. Dhaliwal, an officer of Vaxcyte, Inc.
  • Shares to be sold: 17,000 shares of common stock
  • Estimated aggregate value: $1,153,101.50
  • Shares acquired via exercise of stock options on November 11, 2026
  • Sale to be executed through UBS Financial Services, Inc.
  • Filing date: November 12, 2026

Financial Impact

Sale of 17,000 shares valued at approximately $1.15 million, representing about 0.011% of Vaxcyte's $10.5B market cap.

dilution

Risk Factors

  • Form 144 is an intent to sell; the sale may not be executed.
  • Insider selling could increase if additional officers file similar notices.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
88% bullish (17 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001969223-26-001165
Document: 0001969223-26-001165-index.html0001969223-26-001165
Document: 0001969223-26-001165.txt0001969223-26-001165

Track record

29 reports on PCVX

Performance horizon

5 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +10.87% at T+5 after the Oct 8, 2026 report. 5 of 7 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 3/10 Entry $62.40 Now $61.61 −1.27% settles Dec 15
  2. Nov 12, 20264d ago 144 Neutral 2/10 Viewing Entry $64.69 Now $61.61 −4.76% settles Dec 11
  3. Nov 6, 202610d ago SC 13G/A Neutral 3/10 Entry $63.89 Now $61.61 −3.57% settles Dec 7
  4. Nov 6, 202610d ago SC 13G/A Neutral 3/10 Entry $63.89 Now $61.61 −3.57% settles Dec 7
  5. Nov 4, 202612d ago Insider Cluster Neutral 2/10 Entry $61.92 Now $61.61 −0.50% settles Dec 4
  6. Nov 4, 202612d ago 8-K Neutral 5/10 Entry $61.92 Now $61.61 −0.50% settles Dec 4
  7. Nov 2, 202614d ago 144 Neutral 2/10 Entry $60.81 Now $61.61 +1.32% settles Dec 2
  8. Nov 2, 202614d ago 144 Neutral 2/10 Entry $60.81 Now $61.61 +1.32% settles Dec 2
  9. Oct 9, 20265w ago 8-K Bearish 6/10 Entry $70.65 to $67.53 Now $61.61 +12.80% ▲ +4.42% +1.15% vs SPY
  10. Oct 8, 20265w ago 424B5 Bearish 6/10 Entry $71.38 to $63.89 Now $61.61 +13.69% ▲ +10.49% +4.93% vs SPY
Showing 10 of 29

US Market Status

Market Closed · Opens Wed (11h 35m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 12, 2026